Browsing by Author "Sumit Jaiswal"

Now showing 1 - 6 of 6

Case Report: Rhino-orbital Mucormycosis Related to COVID-19: A Case Series Exploring Risk Factors
(American Society of Tropical Medicine and Hygiene, 2022) Sushil Kumar Aggarwal; Upinder Kaur; Dolly Talda; Akshat Pandey; Sumit Jaiswal; Ahalya Kanakan; Anshuman Singh; Sankha Shubhra Chakrabarti
There has been a surge of rhino-orbital mucormycosis cases in India in the wake of the second wave of the COVID-19 pandemic. It has been widely suggested that dysglycemia resulting from diabetes which is a common comorbidity in COVID-19 patients, and indiscriminate steroid use has resulted in this surge. We report a series of 13 cases of rhino-orbital mucormycosis in COVID-19 patients admitted to our center between mid-April and early June 2021. The cases showed a male preponderance, two patients had loss of vision, and four of them showed intracranial extension of disease. Twelve patients had received steroids and 12 had preexisting or newly diagnosed diabetes, both steroid use and diabetes being the most common identified risk factors. Considering other possible risk factors, immunosuppressed state, antiviral or ayurvedic (Indian traditional) medications, and oxygen therapy were not associated with a definite risk of mucormycosis, because they were not present uniformly in the patients. We propose that COVID-19 itself, through molecular mechanisms, predisposes to mucormycosis, with other factors such as dysglycemia or steroid use increasing the risk. © 2022 American Society of Tropical Medicine and Hygiene. All rights reserved.
Delirium Associated with Diltiazem: Revisiting the Role of L-Type Calcium Channels on Dopaminergic Neurons
(Lippincott Williams and Wilkins, 2025) Ahalya Kanakan; Dondapati Venkata Vamshi Krishna; Sumit Jaiswal; Sankha Shubhra Chakrabarti; Upinder Kaur
[No abstract available]
DRESS Syndrome with Cold Agglutinins: An Unusual Immune Response to Anticonvulsants
(Bentham Science Publishers, 2025) Sumit Jaiswal; Sourabh Pathania; Gaurav Sharma; Ankur Singh; Upinder Kaur; Anup P. Singh; Sankha Shubhra Chakrabarti
Introduction: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a rare adverse drug reaction characterized by cutaneous and systemic manifestations, with a mortality rate of up to 10%. In this study, we describe the case of a 77-year-old man who developed DRESS syndrome with cold agglutination. Case Presentation: A 77-year-old man prescribed phenytoin and carbamazepine for suspected cranial neuralgia after a tooth extraction developed high-grade fever and hemorrhagic crusting on the upper and lower lips and oral mucosa, morbilliform rashes over the chest, abdomen, and back along with facial edema, all occurring over 2 weeks. Clinically significant right-sided submandibular, cervical, and axillary lymphadenopathy was observed. Additional findings, including peripheral blood eosinophilia, hepatitis, and coagulopathy, helped us make a provisional diagnosis of DRESS syndrome. The peripheral blood smear showed an incidental finding of cold agglutination phenomenon at room temperature (16 °C; winter months in North India), which disappeared under warmer conditions. However, gross hemolysis was not confirmed. The patient showed significant response in both clinical and hematological parameters within 24 hours of initiating intravenous dexamethasone, which was continued and gradually tapered over 14 days. Follow-up at one month showed the disappearance of the cold agglutination phenomenon. Conclusion: Cold agglutination in DRESS syndrome has not been documented in detail in the past. One hypothesis is the agglutination of red blood cells (RBCs) due to the effect of the pathogenetic antibodies in DRESS syndrome directed against RBC antigens. Further molecular research may elucidate the pathways of this rare clinical finding. © 2025 Bentham Science Publishers.
Duloxetine-induced neuropsychiatric symptoms in a nonagenarian with chronic Pregabalin intake
(Springer Science and Business Media Deutschland GmbH, 2025) Upinder Kaur; Telagamsetti Sesha Sai Lahari; Sumit Jaiswal; Sankha Shubhra Chakrabarti
[No abstract available]
Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India
(John Wiley and Sons Inc, 2022) Upinder Kaur; Sapna Bala; Bisweswar Ojha; Sumit Jaiswal; Sangeeta Kansal; Sankha S. Chakrabarti
The ChAdOx1 nCoV-19 vaccine (Oxford University-Astra Zeneca) has demonstrated nearly 70% efficacy against symptomatic COVID-19 in trials and some real-world studies. The vaccine was the first to be approved in India in early January 2021 and is manufactured by the Serum Institute of India. Favorable short-term safety data of the vaccine in India in a real-world setting has been recently demonstrated. Here, we report secondary objective (COVID-19 occurrence) measures of the same ongoing prospective observational study in prioritized recipients of the vaccine. The findings are based on participants who could complete at least 2 months of follow-up (n = 1500; female/male: 472/1028; mean age: 38.8 years). Laboratory confirmed SARS-CoV-2 infection was observed in 27/65 participants (41%) who received a single dose and 271/1435 (19%) who received both doses. Specifically, among doctors, 18/27 (66.7%) one dose recipients and 131/377 (34.7%) fully vaccinated developed SARS-CoV-2 infection. The majority of the cases were mild in all groups, and most were breakthrough infections. The occurrence of “severe” COVID-19 was 7.7 times lower (0.4%) in fully vaccinated participants compared to partially vaccinated (3.1%). Four deaths were observed in the study. One of the four deaths was due to sepsis, two due to unspecified cardiac events, and one due to unspecified post-COVID-19 complications. The results of this preliminary analysis necessitate vigorous research on the performance of vaccines against variants, optimal timing of vaccination, and also optimal timings of effectiveness studies to guide future vaccination policy. © 2021 Wiley Periodicals LLC
Pregabalin Induced Maculopapular Eruption in an Elderly Male
(Bentham Science Publishers, 2022) Sumit Jaiswal; Sankha Shubhra Chakrabarti; Tulika Rai; Neeraj Dhameja; Atul Mohan; Vandana Yadav; Upinder Kaur
Background: Pregabalin is used in the treatment of neuropathic pain of various etiolo-gies and as an adjuvant in epilepsy. Blockade of the α2δ subunit of L and N-type Ca-channels is its main mechanism of neurotropic action. Compared to other antiepileptics like phenytoin, valproate and lamotrigine, and other neuropathic pain medications such as amitriptyline and duloxetine, pregabalin has a relatively favorable safety profile and hence is a drug of choice for many geriatri-cians. Case Presentation: Here we describe a case of maculopapular rash induced by pregabalin in an older man, which resolved with withdrawal of the offending drug and conservative management. Conclusion: We have also conducted a literature review of similar cases and highlighted the clinical patterns and management strategies for pregabalin-induced skin rashes. © 2022 Bentham Science Publishers.